Top Highlights From the 2015 European Cancer Congress

References:

1. Yao JC, Fazio N, Singh S, et al. Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, phase 3 RADIANT-4 study. Presented at the 2015 European Cancer Congress; Abstract 5LBA.

2. Brastianos PK, Carter S, Santagata S, et al. Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets. Presented at the 2015 European Cancer Congress; Abstract 2905.

3. Choueiri T, Escudier B, Powles T, et al. Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial. Presented at the 2015 European Cancer Congress; Abstract 4LBA.

4. Van Dam L, Dierickx D, Peccatori F, et al. Obstetrical complications and neonatal outcome in patients diagnosed with acute myeloid and acute lymphoblastic leukemia during pregnancy: Results from the International Network on Cancer, Infertility and Pregnancy (INCIP) study. Presented at the 2015 European Cancer Congress; Abstract 3205.

5. Sparano J, Gray R, Zujewski JA, et al. Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry. Presented at the 2015 European Cancer Congress; Abstract 5BA.

6. Yates L, Knappskog S, Martincorena I, et al. The driver landscape of breast cancer metastasis and relapse. Presented at the 2015 European Cancer Congress; Abstract 1804.